Key result
Low-dose aspirin use and its association with age-related macular degeneration remains controversial, with ongoing randomized controlled trials needed to clarify the risks and benefits.
Why the study?
Does low-dose aspirin increase the risk of age-related macular degeneration?
Does low-dose aspirin increase the risk of age-related macular degeneration?
This commentary discusses the controversy surrounding low-dose aspirin use and its potential association with age-related macular degeneration.
This commentary on the review by Christen and Chew discusses the controversy surrounding aspirin use and its association with age-related macular degeneration (AMD). We address the strength of evidence between low-dose aspirin use and AMD and also discuss the risks and benefits of aspirin use in primary versus secondary prevention of cardiovascular diseases in these cases. We also highlight an ongoing randomized controlled trial in this area.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2014) conducted a review in Age-related macular degeneration. Low-dose aspirin was evaluated. Low-dose aspirin use and its association with age-related macular degeneration remains controversial, with ongoing randomized controlled trials needed to clarify the risks and benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: